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Abstract: This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe
outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE)
prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2), and >3
months to <2 years (stratum 3) had an objectively confirmed diagnosis of VTE treated with standard
of care (SOC) for greater than or equal to3 months, or had completed dabigatran or SOC treatment in
the DIVERSITY trial (NCT01895777) and had an unresolved clinical thrombosis risk factor requiring
further anticoagulation. Children received dabigatran for up to 12 months, or less if the identified
VTE clinical risk factor resolved. Primary endpoints included VTE recurrence, bleeding events, and
mortality at 6 and 12 months. Overall, 203 children received dabigatran, with median exposure being 36.3
(range 0-57) weeks; 171/203 (84.2%) and 32/203 (15.8%) took capsules and pellets, respectively. Overall,
2/203 (1.0%) children experienced on-treatment VTE recurrence, and 3/203 (1.5%) experienced major
bleeding events, with 2 (1.0%) reporting clinically relevant non-major bleeding events, and 37 (18.2%)
minor bleeding events. There were no on-treatment deaths. On-treatment postthrombotic syndrome
was reported for 2/162 (1.2%) children who had deep vein thrombosis or central line thrombosis as their
most recent VTE. Pharmacokinetic/pharmacodynamic relationships of dabigatran were similar to those
in adult VTE patients. In summary, dabigatran showed a favorable safety profile for secondary VTE
prevention in children aged from >3 months to <18 years with persistent VTE risk factor(s).
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Abstract:
This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran
etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years
(stratum 2), and >3 months to <2 years (stratum 3) had an objectively confirmed diagnosis of VTE treated with standard of care (SOC) for
{greater than or equal to}3 months, or had completed dabigatran or SOC treatment in the DIVERSITY trial (NCT01895777) and had an
unresolved clinical thrombosis risk factor requiring further anticoagulation. Children received dabigatran for up to 12 months, or less if the
identified VTE clinical risk factor resolved. Primary endpoints included VTE recurrence, bleeding events, and mortality at 6 and 12 months.
Overall, 203 children received dabigatran, with median exposure being 36.3 (range 0-57) weeks; 171/203 (84.2%) and 32/203 (15.8%) took
capsules and pellets, respectively. Overall, 2/203 (1.0%) children experienced on-treatment VTE recurrence, and 3/203 (1.5%) experienced
major bleeding events, with 2 (1.0%) reporting clinically relevant non-major bleeding events, and 37 (18.2%) minor bleeding events. There
were no on-treatment deaths. On-treatment postthrombotic syndrome was reported for 2/162 (1.2%) children who had deep vein thrombosis
or central line thrombosis as their most recent VTE. Pharmacokinetic/pharmacodynamic relationships of dabigatran were similar to those in adult
VTE patients. In summary, dabigatran showed a favorable safety profile for secondary VTE prevention in children aged from >3 months to
<18 years with persistent VTE risk factor(s).
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 Few children developed recurrent VTE using dabigatran pediatric formulations as 
secondary VTE prophylaxis. 
 Few children experienced major or clinically relevant non-major bleeding events 
























































































































This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to 
describe outcomes in children treated with dabigatran etexilate for secondary venous 
thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 
2 to <12 years (stratum 2), and >3 months to <2 years (stratum 3) had an objectively 
confirmed diagnosis of VTE treated with standard of care (SOC) for ≥3 months, or had 
completed dabigatran or SOC treatment in the DIVERSITY trial (NCT01895777) and had an 
unresolved clinical thrombosis risk factor requiring further anticoagulation. Children received 
dabigatran for up to 12 months, or less if the identified VTE clinical risk factor resolved. 
Primary endpoints included VTE recurrence, bleeding events, and mortality at 6 and 12 
months. Overall, 203 children received dabigatran, with median exposure being 36.3 (range 
0-57) weeks; 171/203 (84.2%) and 32/203 (15.8%) took capsules and pellets, respectively. 
Overall, 2/203 (1.0%) children experienced on-treatment VTE recurrence, and 3/203 (1.5%) 
experienced major bleeding events, with 2 (1.0%) reporting clinically relevant non-major 
bleeding events, and 37 (18.2%) minor bleeding events. There were no on-treatment deaths. 
On-treatment postthrombotic syndrome was reported for 2/162 (1.2%) children who had 
deep vein thrombosis or central line thrombosis as their most recent VTE. 
Pharmacokinetic/pharmacodynamic relationships of dabigatran were similar to those in adult 
VTE patients. In summary, dabigatran showed a favorable safety profile for secondary VTE 
prevention in children aged from >3 months to <18 years with persistent VTE risk factor(s).  
 
























































































































Venous thromboembolism (VTE) in children is associated with considerable morbidity and 
mortality.1-4 Preventing secondary VTE in children poses a challenge for clinicians, due to 
the evolving maturation of a child’s hemostatic system with age, which affects not only the 
risk of recurrent VTE but also the pharmacokinetics and responses to anticoagulants and 
antiplatelet therapies.5,6 Risk factors for recurrent VTE, the presence of comorbidities, failure 
to monitor VTE adequately to inform treatment decisions, and limited vascular access (which 
may impact treatment choice) contribute to treatment complexity.5,6 Risk factors that have 
been reported to be associated with recurrent VTE in children include central venous access 
devices, infection, cancer, congenital heart disease, and thrombophilia.1,7,8  
Current standard of care (SOC) for the secondary prevention of VTE in children, including 
low molecular weight heparins (LMWH) or oral vitamin K antagonists (VKA), depends 
primarily upon the cause and risk factors of the first VTE event, with recurrent VTE 
contributing to the severity and duration of anticoagulation.6 However, current SOC has 
several limitations depending upon the anticoagulant used. For example, LMWH requires 
parenteral administration, whereas VKA may result in variable effects and low time in 
therapeutic range due to frequent food- and drug-drug interactions, requiring the need for 
regular laboratory monitoring to ensure dosing appropriateness of anticoagulation. 
Moreover, the rarity of pediatric VTE leads to difficulties in designing and managing clinical 
trials in this setting.9 The treatment of VTE in children is extrapolated from evidence-based 
recommendations derived from studies performed in adult populations.6 However, the 
hemostatic system in infants and children is profoundly different from adults. As such, 
pediatric safety studies are recommended by both the European Medicines Agency (EMA) 
and the US Food and Drug Administration (FDA).10,11 
Some of the limitations with SOC in children with VTE could be overcome by dabigatran, a 






















































































































prevention of VTE in adults.12-14 In addition, previous pediatric phase 2 dabigatran VTE trials 
have reported similar safety and pharmacokinetic/pharmacodynamic relationships to those 
seen in adults.15-17 In this open-label, phase 3 trial, we report the first safety data on 
dabigatran etexilate for the secondary prevention of VTE in children aged <18 years, as well 
as the appropriateness of an age- and bodyweight-adjusted dosing algorithm for dabigatran 
in this setting. 
Materials and methods 
Trial design 
The trial design has been described in detail previously.18 In brief, this open-label, single-
arm, safety prospective cohort, phase 3 clinical trial (NCT02197416) (supplemental Figure 1) 
is part of a Pediatric Investigational Plan agreed with the EMA Pediatric Committee, and a 
postmarketing requirement agreed with the US FDA. The main objective was to assess the 
safety of dabigatran etexilate for secondary prevention of venous thromboembolism; all 
study outcomes were considered safety related. The current analysis includes the data set 
and target enrollment18 that fulfills the requirements of the EU Pediatric Investigational Plan 
agreed with the EMA Pediatric Committee, while recruitment continued in order to fulfill 
additional US FDA requirements. The trial was conducted in accordance with the Declaration 
of Helsinki and the principles of Good Clinical Practice, and was approved by all 
investigational site ethics committees. Written informed consent from parents or legal 
guardians and pediatric patients (if they were of legal age, or if they reached legal age during 
the trial) was obtained before participation, according to the International Conference on 
Harmonisation Good Clinical Practice, and the regulatory and legal requirements of each 
participating country. 
The trial was sponsored by Boehringer Ingelheim. Listings of trial committees and 






















































































































representatives developed the protocol, supervised the trial, and oversaw any required 
protocol amendments. The external independent data monitoring committee (consisting of 
the same members as for the DIVERSITY trial [NCT01895777]) regularly reviewed safety 
and efficacy data, advising the sponsor on whether the trial should continue, or be modified 
or terminated. An independent blinded adjudication committee evaluated all co-primary 
endpoints to confirm or refute outcome events. Boehringer Ingelheim coordinated the trial 
execution, and oversaw the collection, management, and analysis of trial data. 
Trial population 
Children aged <18 years (stratified by age: stratum 1, 12 to <18 years; stratum 2, 2 to <12 
years; stratum 3, >3 months to <2 years) were eligible if they had an objectively confirmed 
diagnosis of VTE (eg, by compression ultrasound, computerized tomography, or magnetic 
resonance imaging scans) treated with SOC for ≥3 months, or if they had completed 
dabigatran or SOC treatment in the DIVERSITY trial and had an unresolved clinical 
thrombosis risk factor requiring further anticoagulation. Complete inclusion and exclusion 
criteria are provided in supplemental Table 1. 
Treatment 
Patients were treated with open-label dabigatran for up to 12 months, or less if the identified 
clinical risk factor for VTE resolved. An age- and weight-adjusted nomogram according to 
Hayton,19 derived from estimated renal function, was used in order to dose dabigatran and 
achieve comparable exposure to adult populations treated with dabigatran.18 Only one 
dabigatran dose modification (up- or down-titration) according to the nomogram was 
allowed. Different formulations of dabigatran were administered depending upon the age of 
the child; capsules were given to those aged 8 to <18 years, pellets to those aged <8 years 
(or those aged 8 to <12 years unable to swallow capsules); oral solution was offered for 






















































































































ultimately no patient in this trial required oral solution). All patients discontinued dabigatran 
at the end of their trial participation and were switched to SOC if there was a continued need 
for anticoagulation. After completing trial treatment, patients were followed up for a period of 
28 days. Patients who discontinued trial treatment prematurely were to be followed up 
according to the remaining visit schedule until the end of the trial or at least for 28 days. 
Therefore, patients who discontinued trial treatment prematurely and had a follow-up period 
of at least 28 days were not considered as premature trial discontinuations. Patients who 
completed trial treatment as planned, but did not have a follow-up period of at least 28 days, 
were considered premature trial discontinuations but not premature treatment 
discontinuations. Patients who discontinued trial treatment due to resolution of the 
underlying risk factor were not considered premature treatment discontinuations. 
Outcomes 
According to the objectives of the study, all outcomes were considered safety related. 
Primary endpoints were: recurrence of VTE assessed at 6 and 12 months postenrollment 
(defined as all recurrent VTE—contiguous progression or noncontiguous new thrombus, 
including deep vein thrombosis, pulmonary embolism, and paradoxical embolism confirmed 
by imaging); mortality (overall and thrombotic/thromboembolic event mortality) at 6 and 
12 months; major bleeding events (MBEs) at 6 and 12 months (defined as: fatal bleeding; 
clinically overt bleeding [≥20 g/L decrease in hemoglobin over 24-hours]; retroperitoneal, 
pulmonary, or bleeding that involves the central nervous system; or bleeding that requires 
surgical intervention in an operating suite); clinically relevant nonMBEs (CRNMBEs) at 6 and 
12 months (defined as: overt bleeding that is not directly attributable to the patient’s 
underlying medical condition and requires administration of a blood product, or bleeding that 
requires medical or surgical intervention other than in an operating suite to restore 






















































































































macroscopic evidence of bleeding that does not fulfill the MBE or CRNMBE criteria); and 
overall mortality and thrombotic/thromboembolism-related mortality.20 
Secondary endpoints included: the occurrence of newly diagnosed or worsening of baseline 
postthrombotic syndrome (PTS; as per the modified Villalta scale21,22) at 6 and 12 months 
postenrollment; the relationship between plasma dabigatran concentrations (total plasma 
dabigatran trough levels measured at a central laboratory [Nuvisan GmbH, Neu-Ulm, 
Germany] by a validated high-performance liquid chromatography–tandem mass 
spectrometry assay) and pharmacodynamic markers (diluted thrombin time [dTT], activated 
partial thromboplastin time [aPTT], and ecarin clotting time [ECT] evaluated at a central 
laboratory [Menal GmbH, Emmendingen, Germany]); the number of patients with dose 
adjustments, and the acceptability of the administered formulations. The residual effect 
period for which events were still considered on-treatment following the last intake of trial 
medication was 3 days. 
Statistical analysis 
Boehringer Ingelheim were responsible for data collection and statistical analysis, and all 
authors had access to trial data. Based upon an estimated 5% event rate for the composite 
of recurrent VTE, major bleeds, and mortality related to thromboembolic event at 12 months, 
a sample size of 100 patients would provide >99% probability observing at least one event. 
However, if the event rate was 1%, it would still provide >63% probability of observing at 
least one event. While designed to evaluate 100 patients, the sample size was subsequently 
increased to 200 patients to meet FDA regulatory authority requests. For the primary 
endpoints and the secondary PTS endpoint at 6 and 12 months postenrollment, time-to-
event analyses were summarized as Kaplan–Meier estimates, along with descriptive rates. 
Subgroup analyses included age strata and sex. For the descriptive analyses, patients with 
early withdrawal or who were lost to follow-up were deemed nonevents. Patients were 






















































































































have VTE or bleeding episodes. A sensitivity analysis was also conducted including all 
patients entered in the study and the full study period from entry until the day of the last 
follow-up visit, or until they were lost to follow-up, death, or consent was withdrawn (“on-
treatment plus follow-up”). The pharmacokinetic/pharmacodynamic full analysis set 
consisted of all patients with ≥1 postbaseline measurement. Pharmacokinetic results were 
summarized descriptively. Pharmacokinetic/pharmacodynamic relationships were explored 
using graphical analyses. Safety and adverse events were summarized descriptively. 
Results 
Participants and follow-up 
At European Union database lock in March 2019, 204 patients from 60 sites in 22 countries 
had entered the trial, with 1 adolescent not treated (due to inability to take treatment) (Figure 
1). The median exposure to dabigatran was 36.3 (range 0-57) weeks. Risk factors resolved 
in 32 children during the trial, leading to treatment discontinuation. In 56/203 (27.6%) 
children, treatment was discontinued prematurely for the following reasons: target dabigatran 
concentration not achieved after one dose modification (n = 25), noncompliance with 
protocol (n = 4), VTE recurrence (n = 3; however, one of these VTE events was not 
confirmed to be a VTE recurrence by the adjudication committee and therefore was not 
included in the analysis), worsening of other pre-existing disease (n = 2), other adverse 
events (n = 4), consent withdrawn regarding dabigatran treatment (n = 2), and other (n = 16). 
The trial was discontinued prematurely (28-day follow-up period not completed as planned) 
in 24/203 (11.8%) children, with reasons being adverse events (n = 3), noncompliance with 
trial protocol (n = 2), consent withdrawn (n = 5), and other (n = 14). Only 4 patients 
discontinued both treatment and trial prematurely. All other patients who discontinued the 
trial prematurely completed the treatment period as planned, but discontinued the trial during 






















































































































203 treated children, 115 (56.7%) were children receiving chronic anticoagulation, who were 
newly exposed to dabigatran, and 88 (43.3%) were rolled over from the DIVERSITY trial (59 
[29.1%] previously treated with dabigatran and 29 [14.3%] with SOC). No children required 
oral solution; 171/203 (84.2%) and 32/203 (15.8%) took capsules and pellets, respectively. 
Overall, 113/203 (55.7%) children were male, 101/203 (49.8%) were Central European, and 
185/203 (91.1%) were white. Low molecular weight heparin was the most frequently used 
prior anticoagulant, prescribed for 152/203 (74.9%) children. Deep vein thrombosis other 
than central line related thrombosis and cerebral venous thrombosis was the most frequent 
VTE, reported in 154/203 (75.9%) of children and 35/203 (17.6%) children had PTS at 
baseline.  
Information on previous VTE and baseline medical conditions with increased risk of 
thrombosis was available for 199 out of 203 patients. Prior confirmed VTE (before the index 
[most recent] VTE event in this trial) was reported by 36/199 (18.1%) children (range of 2-6 
confirmed VTE events including the most recent event) (Table 2). Previous VTE was 
reported as being unprovoked in 25/36 (69.4%) and provoked in 13/36 (36.1%) children. 
There were 35 of 199 (17.6%) children who had PTS at baseline. The most common medical 
conditions with increased risk of thrombosis were congenital heart disease (12/199 [6.0%]), 
hematologic cancer (11/199 [5.5%]), and the presence of a central venous line or catheter 
(11/199 [5.5%]). Inherited thrombophilia was reported in 91/203 (44.8%) children; of these, 
the following disorders were reported: factor V Leiden mutation 34 (16.7%), prothrombin 
mutation 17 (8.4%), antithrombin deficiency 20 (9.9%), protein C/S deficiency 23 (11.3%), 
and other coagulation disorders 23 (11.3%). Of other conditions requiring secondary VTE 
























































































































Overall, 2/203 (1.0%) children experienced recurrent VTE, one within 3 months of treatment 
and the other one within 6 months of treatment (Table 3 and Figure 2A). Both were female 
adolescents who had had deep vein thrombosis (n = 1) and pulmonary embolism (n = 1) as 
their most recent VTE event. Clinical risk factors that required secondary VTE protection 
were methylenetetrahydrofolate reductase (MTHFR) A1298C homozygous mutation in one 
female whose most recent VTE event was 3.5 months previously. In the other female, whose 
most recent VTE event was 26 months previously, they were MTHFR A1298C, plasminogen 
activator inhibitor-1 46156 heterozygote mutation, and protein S deficiency. The probability 
of freedom from recurrent VTE at 12 months across all age strata during the on-treatment 
period was 0.988 (95% confidence interval [CI], 0.951-0.997). Consistent results were 
observed for the full study period: on-treatment plus follow-up (probability of freedom from 
recurrent VTE at 12 months, 0.952; CI, 0.900-0.977). 
The probability of freedom from bleeding at 12 months during the on-treatment period was 
0.752 (95% CI, 0.672-0.815). Consistent results were observed for the full study period: on-
treatment plus follow-up (probability of freedom from bleeding at 12 months, 0.771; CI, 
0.699-0.827). Of the 40/203 (19.7%) children reporting bleeding events, 1.5% (3/203) were 
MBEs, 1.0% (2/203) were CRNM bleeding events, and 18.2% (37/203) were minor bleeding 
events (Table 3). The location of investigator-reported on-treatment bleeding events with 
dabigatran is shown in supplemental Table 2. Of the 3 children reporting MBEs, one was a 
17-year-old female with an MBE originating from a venous varix in the right leg, and was 
treated with idarucizumab (Praxbind®) to reverse dabigatran in the context of a clinical trial 
(NCT02815670); one was a 16-year-old male who experienced an extrapleural hematoma 
following surgery, 3 days after a temporary interruption of dabigatran for planned surgery; 
and one was a 17-year-old male with thrombophilia and positive tests for homocysteinemia, 
high levels of lupus anticoagulant, and anti-cardiolipin antibodies who presented with an 
episode of hemoptysis and the treatment with dabigatran was switched to another 






















































































































after stopping dabigatran treatment. For the 2 children reporting CRNMBEs, one was a 17-
year-old male who experienced a cut in a finger that required medical/surgical intervention 
(stitches) to achieve hemostasis, and one was a 10-year-old female who presented with 
heavy menses after starting her menstrual cycle. There were no deaths while patients were 
on treatment.  
Secondary endpoints 
In total, PTS was newly reported in 2 adolescent males out of 162 patients (1.2%) who had 
DVT or central line thrombosis as their most recent VTE (Table 3 and Figure 2B)—one 
within 3 months and the other within 3-6 months of treatment. The probability of freedom 
from newly diagnosed PTS at 12 months across all age strata during the on-treatment period 
was 0.985 (95% CI, 0.939-0.996). Consistent results were observed for the full study period: 
on-treatment plus follow-up (probability of freedom from newly diagnosed PTS at 12 months, 
0.980; 95% CI, 0.938-0.993). Clinical risk factors that required secondary VTE protection in 
these patients were i) factor V Leiden (heterozygous mutation) and prothrombin mutation 
(homozygous mutation) in one male whose most recent VTE event was 3 months previously 
(Modified Villalta score 2), and ii) factor V Leiden (heterozygous mutation), prothrombin 
(heterozygous mutation), and complete occlusion of the vena cava in one male whose most 
recent VTE event was 11.5 months previously (Modified Villalta score 3). 
Adverse events were reported by 152/203 (74.9%) of children, with the most common being 
nasopharyngitis (34/203 [16.7%]), headache (33/203 [16.3%]), and abdominal pain (21/203 
[10.3%]) (Table 4). Serious adverse events were experienced by 25/203 (12.3%) of children, 
and adverse events leading to treatment discontinuation were reported by 12/203 (5.9%) 
children.  
At end of treatment, according to investigators, 124/126 (98.4%) and 16/17 (94.1%) children 
had good or satisfactory acceptance of capsules and pellets, respectively, and were able to 






















































































































pellets, respectively) (supplemental Table 3). Overall, dabigatran geometric mean (gCV%) 
trough exposure over all visits was 88.8 ng/mL (42.6); across age strata it was 96.5 ng/mL 
(34.8) for children aged 12 to <18 years (n = 153), 74.7 ng/mL (37.1) for those aged 2 to <12 
years (n = 38), and 40.9 ng/mL (97.1) for those aged from >3 months to <2 years (n = 8) 
(supplemental Table 4). Pharmacokinetic/pharmacodynamic curves showed a linear 
relationship between total dabigatran plasma concentration and dTT and ECT, and a 
nonlinear relationship between total dabigatran plasma concentrations and activated partial 
thromboplastin time (Figure 3). During the on-treatment period, 26.1% of patients had a dose 
adjustment (increase or decrease of dose). 
Discussion 
This trial is the first to describe clinical outcomes in children aged <18 years being treated 
with dabigatran etexilate for secondary VTE prevention. We observed a low frequency of 
recurrent VTEs and few MBEs or CRNMBEs during dabigatran treatment in this setting. The 
rate of newly diagnosed PTS with dabigatran treatment in the study was 2/162 (1.2%). Using 
an age- and bodyweight-adjusted dosing algorithm, dabigatran plasma trough exposure was 
similar to that observed in adults.16 In addition, the dabigatran 
pharmacokinetic/pharmacodynamic relationship seen in this pediatric population was similar 
to that seen in the adult setting.23  
In terms of antithrombotic effect, the DIVERSITY trial has shown similar efficacy for 
dabigatran vs SOC when treating children aged <18 years with acute VTE, as well as the 
suitability of a pediatric dabigatran-dosing algorithm.24 In that trial, there was a slightly higher 
frequency of recurrent VTE in children being treated with dabigatran for acute VTE (3.8%) 
than in this trial (1.0%).24 This difference likely reflects the time since the index VTE event 






















































































































Our study population was comprised of approximately 20% of patients with the so-called 
high-risk inherited thrombophilia (protein S/C or antithrombin deficiency) and an additional 
10% of patients with antiphospholipid syndrome (APS). In comparison, European 
investigators analysed a multicenter German–Israeli database to study the impact of 
genetically confirmed, high-risk, inherited thrombophilia on recurrent VTE in children and 
adults after cessation of anticoagulation.25 A cumulative incidence of thrombosis recurrence 
of approximately 4% was observed at 12 months of follow up among pediatric patients.25 A 
different analysis of the same database suggests these patients may have been off 
anticoagulation between 3 and 9 months after their event,26 which could explain their higher 
frequency of thrombosis recurrence. Additionally, 2 pediatric studies on APS in patients with 
arterial and venous thrombosis reported recurrence of thrombosis rates of 19% and 29% 
with mean follow-up periods of 6.1 and 5.7 years, respectively.27,28 While the follow-up 
duration of those studies was longer than in our study, and the participants of those may not 
match our study population, these comparisons contribute to placing the overall VTE 
recurrence rate reported herein in the context of the literature. To address the issue of lupus 
anticoagulants and direct oral anticoagulants (DOACs) in adult patients with high-risk, triple-
positive APS, a lack of benefit and increased thrombotic risk has been reported following 
treatment with the direct factor Xa inhibitor rivaroxaban compared with warfarin,29 raising the 
question of whether all DOACs should be avoided in this setting. However, as dabigatran 
has a different mode of action and directly inhibits thrombin, dabigatran might potentially 
lead to a more beneficial outcome in such patients. Indeed, a post-hoc pooled analysis of the 
RE-COVER/RE-COVER II and RE-MEDY trials found no significant differences in efficacy 
and safety between dabigatran and warfarin in adult patients with APS.30 Of note, APS-
positive patients comprised a small number of subjects enrolled (71 treated with dabigatran 
vs. 80 treated with warfarin), and a distinction between high risk or regular APS status was 
not included.30 At present, prospective data regarding the efficacy and safety of dabigatran in 






















































































































Importantly, our trial results compare favorably to prior reports of VTE recurrence in the 
pediatric population. In the REVIVE trial, an open-label, pediatric, randomized, controlled 
study where the LMWH reviparin was compared to unfractionated heparin/VKA to treat VTE, 
the rate of venous thrombosis recurrence or death of patients treated with LMWH was 
5.6%.31 Similarly, a meta-analysis of LMWH pediatric studies reported pooled incidence 
rates for the development of recurrent VTE on LMWH secondary prophylaxis as being 
5.2%,32 while other LMWH pediatric dose-finding studies have reported VTE recurrence 
rates of 3%.33 
In both trials, the frequency of any bleeding events on treatment with dabigatran was similar 
(19.7% in this trial and 19.9% in DIVERSITY), with a low incidence of MBEs in both studies 
(1.5% in this trial and 2.6% in DIVERSITY). Our bleeding complications align with results in 
the pediatric literature. The REVIVE trial with the LMWH reviparin reported a major bleeding 
rate of 5.6%.31 Likewise, a meta-analysis of LMWH pediatric studies reported a pooled 
incidence rate for major bleeding of 1.8% and 6.5% for once-daily and twice-daily 
administration, respectively.32  
In relation to newly diagnosed PTS, the incidence of 1.2% (all cases being possible mild 
ones) raises the concern as to whether these data were evaluated prematurely. Of note, the 
last official recommendation from the International Society on Thrombosis and Haemostasis 
Subcommittee stated that possible PTS should be detected after 6 months from the index 
limb deep vein thrombosis, and definitive PTS after 12 months.34 Interestingly, almost 70% 
of the index VTEs were unprovoked, a known risk factor for PTS in children.35,36 
Furthermore, the baseline PTS detected for patients with previous VTE was 17%, which is 
lower than the weighted mean (43%, 95%CI, 38%-48%) reported for pediatric PTS detected 
retrospectively.21 Contemporary work investigated if direct oral anticoagulants (ie, 
rivaroxaban) can reduce the rate of PTS in adults with limb deep vein thrombosis in 
comparison to LMWH/VKA by providing a more stable anticoagulation, but this protective 






















































































































1.13).37 Recently, this suspicion arose again in adults treated with rivaroxaban (OR, 0.5; 
95% CI, 0.3-0.9: P = 0.02).38 Our low PTS rate will need to be re-evaluated after a longer 
follow-up. In our trial, <75% of children experienced adverse events,12% reported serious 
adverse events, and <6% of children discontinued treatment because of an adverse event. 
These data are comparable to adult patients treated in the pivotal VTE trials of dabigatran, 
apixaban and rivaroxaban. In the RE-COVER, RE-MEDY and RE-SONATE trials, 66–71% 
of patients treated with dabigatran experienced adverse events, 7–16% reported serious 
adverse events, and 7–9% discontinued treatment because of an adverse event.13,14 
Similarly, in the AMPLIFY and EINSTEIN trials, 67–71% and 63% of patients treated with 
apixaban and rivaroxaban, respectively, experienced adverse events, 13–16% and 12% 
reported serious adverse events, and 6–8% and 5% discontinued treatment because of an 
adverse event.39-41 
Finally, an analysis of dabigatran pharmacokinetic/pharmacodynamic data from previous 
pediatric and adult trials indicates that the most appropriate assays for dabigatran might be 
dTT and ECT,42 which is further supported by data from this trial, as well as the DIVERSITY 
trial.24 Developmental changes in the hemostatic system had little effect on dabigatran 
pharmacokinetic/pharmacodynamic relationships, with children aged <2 months being the 
possible exception.42 A pharmacokinetic simulation analysis of dabigatran exposure in 
pediatric patients (data on-file) has indicated that the impact of dose adjustments on overall 
exposure is minimal. Therefore, it is considered appropriate to follow an age- and weight-
adjusted dosing algorithm in pediatric patients without monitoring of dabigatran plasma 
levels. 
Our trial did not have a comparator arm, yet the present safety data complement the 
dabigatran safety data from DIVERSITY that does have a comparator arm and showed 
similar efficacy and safety of dabigatran vs SOC in pediatric patients treated for acute VTE.24 






















































































































assessment during the study was also variable, given the variability in lag time from VTE 
diagnosis to enrollment in this study of extended VTE treatment.  
In view of the low patient numbers and different risk profile of patients in stratum 3 (age >3 
months to <2 years), our data cannot be extrapolated with absolute confidence to younger 
patients. Based upon the inclusion criteria and the study population (i.e., >60% unprovoked 
VTE), our findings apply most directly to pediatric patients with unprovoked VTE and those 
who require extended anticoagulant therapy (i.e., beyond 3 months post-VTE diagnosis). A 
final limitation is the exclusion of patients with early withdrawal from the study medication 
due to failing to reach target dabigatran concentrations not included in the main analyses. 
However, the results of the sensitivity analyses that included all patients entered, and the full 
study period (on-treatment plus follow-up), were consistent with those of the primary 
analyses. Moreover, the comparison of baseline patient and thrombus characteristics 
between patients withdrawn due to failing to reach target dabigatran concentrations vs the 
retained population show that there are no statistical differences in the 2 groups 
(supplemental Table 5). 
In conclusion, this trial has shown favorable safety of pediatric formulations of dabigatran for 
secondary prevention of VTE in children aged from >3 months to <18 years with persistent 
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Table 1. Baseline patient demographics and characteristics by age strata 
 Dabigatran  
Total 
N = 203 
 12 to <18 y 
n = 153 
2 to <12 y 
n = 42 
0 to <2 y 
n = 8 




153 (100.0)  
0 
 
18 (42.9)  
24 (57.1)  
 
0  




Age, y, mean (SD) 15.1 (1.6) 7.0 (3.0) 0.6 (0.5) 12.8 (4.5) 
Male, n (%) 87 (56.9)  21 (50.0)  5 (62.5)  113 (55.7) 
Region, n (%)     
Central/Eastern Europe 73 (47.7)  21 (50.0)  7 (87.5)  101 (49.8) 
Western Europe 35 (22.9)  12 (28.6)  0 47 (23.2) 
North America 37 (24.2)  5 (11.9)  1 (12.5)  43 (21.2) 
Latin America 5 (3.3) 2 (4.8)  0 7 (3.4) 
Asia 2 (1.3)  1 (2.4)  0 3 (1.5) 
Israel 1 (0.7)  1 (2.4)  0 2 (1.0) 
Race,† n (%)     
White 141 (92.2)  37 (88.1)  7 (87.5)  185 (91.1) 
Asian 6 (3.9)  1 (2.4)  0  7 (3.4) 
Black or African American 4 (2.6)  3 (7.1)  0 7 (3.4) 
Multiple 1 (0.7)  1 (2.4)  1 (12.5)  3 (1.5) 
Body mass index, kg/m
2
, mean (SD) 24.7 (5.4) 17.8 (2.4) 16.1 (1.2) 22.9 (5.7) 
eGFR,‡ mL/min/1.73 m2, mean (SD) 101.3 (26.6) 128.5 (25.2) 125.6 (15.7) 107.8 (28.3) 
Source of patients 
Chronically anticoagulated children 
newly exposed to dabigatran 
Rollover patients treated with 
dabigatran in the DIVERSITY trial 
Rollover patients treated with SOC 
in the DIVERSITY trial 
 
82 (53.6)  
 
 
46 (30.1)  
 
25 (16.3)  
 
26 (61.9)  
 
 
12 (28.6)  
 
4 (9.5)  
 
7 (87.5)  
 
 










Prior anticoagulation treatment,§ n (%) 
Low-molecular-weight heparin 
Vitamin K antagonist 
Unfractionated heparin 




116 (75.8)  
61 (39.9)  
46 (30.1)  
46 (30.1) 
1 (0.7)  
14 (9.2)  
 
29 (69.0)  
11 (26.2)  
10 (23.8)  
12 (28.6) 
0 
1 (2.4)  
 
7 (87.5)  
1 (12.5)  
2 (25.0)  































































































































Most recent venous thromboembolic 
event,¶ n (%) 
DVT (other than central line and 
cerebral venous thrombosis) 
Pulmonary embolism 
Central line thrombosis 
Cerebral venous thrombosis and/or 
sinus thrombosis 
DVT (other than central line and 
cerebral venous thrombosis) or 
central line thrombosis 
 
 
126 (82.4)  
 
19 (12.4)  
2 (1.3)  
8 (5.2) 
 
128 (83.7)  
 
 
24 (57.1)  
 
1 (2.4)  
3 (7.1)  





5 (62.5)  
 
0 
2 (25.0)  












Risk factors for venous 
thromboembolism, n (%) 
1 prespecified# risk factor 
≥2 prespecified# risk factor 














5 (62.5)  
2 (25.0)  






DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; SD, standard deviation; SOC, 
standard of care; VTE, venous thromboembolism. 
*One adolescent was not treated. 
†Missing data for one adolescent. 
‡Calculated using the Schwartz formula. 
§Nonanticoagulation therapy was used to treat the most recent VTE in 5 adolescents, 2 children aged 
2 to <12 years, and one child aged from >3 months to <2 years. 
‖Rollover patients treated with dabigatran in the DIVERSITY trial 
¶Patients could be assessed with more than one type of most recent VTE. 
#Defined as inherited thrombophilia, short bowel syndrome, congenital nephrotic syndrome, 
inflammatory bowel disease, recent immobilization, presence of central venous/arterial line or 
catheter, total parental nutrition, systemic lupus erythematosus, systemic sclerosis or inflammatory 
vasculopathies, recurrent idiopathic (unprovoked) VTE, structural venous abnormality, 
antiphospholipid and/or lupus antibodies. 























































































































Table 2. Baseline risk factors for VTE by age strata 
 Dabigatran   
Total  12 to <18 y 2 to <12 y 0 to <2 y 
Medical history of previous 
thromboembolic events 
n = 150 n = 41 n = 8 N = 199* 
History of prior VTE event (before the index  
VTE event in this trial), n (%) 
    
Yes 28 (18.7)  6 (14.6)  2 (25.0)  36 (18.1) 
Number of prior confirmed VTE events†     
2 9 (6.0)  1 (2.4)  0 10 (5.0) 
3 13 (8.7)  4 (9.8)  1 (12.5)  18 (9.0) 
4 4 (2.7)  0 0 4 (2.0) 
5 1 (0.7)  0 0 1 (0.5) 
6 1 (0.7)  1 (2.4)  1 (12.5)  3 (1.5) 
No 122 (81.3)  35 (85.4)  6 (75.0)  163 (81.9) 
Previous VTE,‡ n (%) n = 28 n = 6 n = 2 n = 36 
Unprovoked 21 (75.0)  3 (50.0)  
4 (66.7)  
1 (50.0)  
2 (100.0)  
25 (69.4) 
13 (36.1) Provoked 7 (25.0)  
Postthrombotic syndrome,§ n (%) 29 (19.3)  5 (12.2)  1 (12.5)  35 (17.6) 
Medical conditions/circumstances with 
increased risk of thrombosis, n (%) 
n = 150 n = 41 n = 8 N = 199* 
Congenital heart disease 6 (4.0)  3 (7.3)  3 (37.5)  12 (6.0) 
Hematologic cancer 4 (2.7)  7 (17.1)  0  11 (5.5) 
Presence of central venous line 3 (2.0)  4 (9.8)  4 (50.0)  11 (5.5) 
Recent immobilization‖ 7 (4.7) 0 0 7 (3.5) 
Any history of solid cancer 1 (0.7) 2 (4.9)  1 (12.5)  4 (2.0) 
Presence of other venous or arterial catheter 2 (1.3)  1 (2.4)  0 3 (1.5) 
Hypertension 3 (2.0) 0 0 3 (1.5) 
Heart failure 0 1 (2.4) 1 (12.5)  2 (1.0) 
History of stroke or transient ischemic attack 0 1 (2.4) 0 1 (0.5) 
Liver disease (currently not active) 0 0 1 (12.5) 1 (0.5) 
History of major or clinically relevant 
bleeding event 
0 1 (2.4) 0 1 (0.5) 
Total parenteral nutrition−dependency 1 (0.7) 0 0 1 (0.5) 
Clinical risk factors requiring secondary 
VTE prevention, n (%) 
n = 153 n = 42 n = 8 N = 203 
Inherited thrombophilia¶,# 79 (51.6)  11 (26.2) 1 (12.5) 91 (44.8) 
Factor V Leiden mutation** 32 (20.9)  2 (4.8)  0 34 (16.7) 
Prothrombin mutation†† 15 (9.8)  2 (4.8)  0 17 (8.4) 
Antithrombin deficiency 16 (10.5)  4 (9.5) 0 20 (9.9) 
Protein S/C deficiency 19 (12.4)  4 (9.5)  0 23 (11.3) 
Other‡‡ 20 (13.1)  2 (4.8)  1 (12.5)  23 (11.3) 
2 or more thrombophilia conditions   26 (17.0) 4 (9.5) 0 30 (14.8) 






















































































































Other conditions requiring secondary 
VTE prophylaxis, n (%) 
n = 153 n = 42 n = 8 N = 203 
Antiphospholipid antibodies and/or lupus 
antibodies 
18 (11.8)  1 (2.4)  1 (12.5)  20 (9.9) 
Recurrent unprovoked VTE 21 (13.7)  7 (16.7)  1 (12.5)  29 (14.3) 
Structural venous abnormality§§ 20 (13.1)  6 (14.3)  0 26 (12.8) 
Any other risk factor requiring secondary 
prophylaxis 
47 (30.7)  18 (42.9)  6 (75.0)  71 (35.0) 
CRF, clinical report form; GP, glycoprotein; MTHFR, methylenetetrahydrofolate reductase; MTRR, 
methionine synthase reductase; PAI, plasminogen activator inhibitor; VTE, venous thromboembolism. 
*Medical history of previous VTE was collected starting CRF Version 2; missing data for 4 children 
who were assessed with CRF Version 1. 
†Includes the most recent VTE event. 
‡Children may be counted in >1 category. Percentages based on the number of patients with a 
history of prior VTE events. Missing data for 163 children. 
§Missing data for one adolescent. 
‖Illness requiring bed rest or involving paralysis. 
¶The number of children with ≥1 of the conditions listed. 
#Missing data for 2 adolescents and 2 children ages 2 to <12 years. 
**Gln506 (rs6025), hetero- or homozygous. 
††G20210A mutation. 
‡‡Other coagulation disorders/thrombophilias including: MTHFR mutation, MTRR mutation, PAI 
4G/5G polymorphism, factor XII deficiency, integrin A2 mutation, hyperhomocysteinemia, fibrinogen 
mutation, GP IA mutation, GP IIIA mutation, factor VIII elevation. 
§§Structurally abnormal venous system, eg, inferior vena cava malformation, Paget-Schroetter 






















































































































Table 3. On-treatment VTEs, postthrombotic syndrome, bleeding events, and fatal 
events at 12 months by age strata (treated set)  
 Dabigatran   
Total 
N = 203 
12 to <18 y 
n = 153 
2 to <12 y 
n = 42 
0 to <2 y 
n = 8 
Recurrent VTE event, n (%) 2 (1.3)  0 0 2 (1.0) 
Subgroup analysis,* n/N (%)     
Sex     
Male 0/87 (0.0) 0/21 (0.0) 0/5 (0.0) 0/113 (0.0) 
Female 2/66 (3.0) 0/21 (0.0) 0/3 (0.0) 2/90 (2.2) 
Postthrombotic syndrome,† n (%) 2/128 (1.6) 0/27 (0.0) 0/7 (0.0) 2/162 (1.2) 
Subgroup analysis,* n/N (%)     
Sex     
Male 2/80 (2.5) 0/12 (0.0) 0/5 (0.0) 2/97 (2.1) 
Female 0/48 (0.0) 0/15 (0.0) 0/2 (0.0) 0/65 (0.0) 
Bleeding events, n (%) 37 (24.2) 2 (4.8)  1 (12.5)  40 (19.7) 
Major 3 (2.0)  0 0 3 (1.5) 
Clinically relevant non-major 1 (0.7)  1 (2.4)  0 2 (1.0) 
Minor 34 (22.2)  2 (4.8)  1 (12.5)  37 (18.2) 
All-cause death, n (%) 0 0 0 0 
VTE, venous thromboembolism. 
*Missing data for one adolescent. 
†Calculated over the number of patients with DVT (other than central line and cerebral venous 






















































































































Table 4. Summary of adverse events, and adverse events occurring in ≥5% of children in either treatment group (treated set) 
All data are n (%) 
Dabigatran  
Total 
N = 203 
12 to <18 y 
n = 153 
2 to <12 y 
n = 42
 
0 to <2 y 
n = 8 
Children with any adverse event 120 (78.4)  25 (59.5)  7 (87.5)  152 (74.9) 
Drug-related adverse event* 37 (24.2)  5 (11.9)  1 (12.5)  43 (21.2) 
Children with serious adverse events† 19 (12.4)  6 (14.3)  0 25 (12.3) 
Leading to death 0 0 0 0 
Life-threatening 2 (1.3)  0 0 2 (1.0) 
Requiring hospitalization 17 (11.1)  6 (14.3)  0 23 (11.3) 
Prolonging hospitalization 1 (0.7)  1 (2.4)  0 2 (1.0) 
Other 2 (1.3)  2 (4.8)  0 4 (2.0) 
Children with adverse events of special interest‡ 0 0 0 0 
Children with adverse events leading to treatment 
discontinuation 
9 (5.9) 2 (4.8)  1 (12.5)  12 (5.9) 
Adverse events in ≥5% of children overall   
Nasopharyngitis 26 (17.0)  7 (16.7) 1 (12.5)  34 (16.7) 
Drug-related 0 0 0 0 
Serious adverse event 0 0 0 0 
Headache 27 (17.6)  6 (14.3)  0 33 (16.3) 
Drug-related 2 (1.3)  1 (2.4)  0 3 (1.5) 
Serious  0 1 (2.4) 0 1 (0.5) 
Abdominal pain§ 19 (12.4)  2 (4.8)  0 21 (10.3) 
Drug-related 5 (3.3) 2 (4.8) 0 7 (3.4) 
Serious  1 (0.7)  0 0 1 (0.5) 
Respiratory tract infection‖ 15 (9.8)  3 (7.1) 0 18 (8.9) 






















































































































Serious  1 (0.7) 0 0 1 (0.5) 
Nausea 13 (8.5)  3 (7.1)  0 16 (7.9) 
Drug-related 5 (3.3)  2 (4.8)  0 7 (3.4) 
Serious  0 0 0 0 
Vomiting  10 (6.5)  4 (9.5)  0 14 (6.9) 
Drug-related 1 (0.7)  1 (2.4)  0 2 (1.0) 
Serious  0 0 0 0 
Cough 9 (5.9)  4 (9.5)  1 (12.5)  14 (6.9) 
Drug-related 0 0 0 0 
Serious  0 0 0 0 
Dyspepsia 13 (8.5)  0 0 13 (6.4) 
Drug-related 9 (5.9)  0 0 9 (4.4) 
Serious  0 0 0 0 
Pyrexia 11 (7.2)  2 (4.8)  0 13 (6.4) 
Drug-related 0 0 0 0 
Serious  0 0 0 0 
Diarrhea 12 (7.8)  1 (2.4)  0 13 (6.4) 
Drug-related 2 (1.3)  0 0 2 (1.0) 
Serious  0 0 0 0 
Pain in extremity 11 (7.2)  2 (4.8)  0 13 (6.4) 
Drug-related 0 0 0 0 
Serious  1 (0.7)  0 0 1 (0.5) 
Epistaxis 10 (6.5)  1 (2.4)  1 (12.5)  12 (5.9) 
Drug-related 5 (3.3)  1 (2.4)  1 (12.5)  7 (3.4) 
Serious  0 0 0 0 
*Investigator-defined. 






















































































































‡Protocol-defined adverse events of special interest were elevated aspartate aminotransferase and/or alanine aminotransferase >3-fold upper limit of normal 
combined with an elevation of total bilirubin >2-fold upper limit of normal measured in the same blood draw sample, and a ≥2-fold increase in creatinine from 
baseline levels that is above the upper limit of normal. 
§Includes children with upper abdominal pain. 























































































































Figure 1. Disposition of patients. 
Figure 2. Kaplan–Meier curves for all age strata combined (on-treatment) for time to (A) 
recurrent VTE and (B) postthrombotic syndrome (adjudicated data from the treated set). 
VTE, venous thromboembolism. 
Figure 3. PK–PD relationship curves at trough sampling times for dabigatran PK and dTT 
(A, overall; B, aged 12 to <18 years; C, aged 2 to <12 years; D, aged from >3 months to <2 
years), aPTT (E, overall; F, aged 12 to <18 years; G, aged 2 to <12 years; H, aged from >3 
months to <2 years), and ECT (I, overall; J, aged 12 to <18 years; K, aged 2 to <12 years; L, 
aged from >3 months to <2 years) by age group. aPTT, activated partial thrombin time; 
Dabititrn, dabigatran titration; dTT, diluted thrombin time; ECT; ecarin clotting time; PD, 
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